Glucoheptoamidated polyamidoamine PAMAM G3 dendrimer as a vehicle for succinate linked doxorubicin; enhanced toxicity of DOX against grade IV glioblastoma U-118 MG cells

Glioblastoma multiforme (GBM), known as astrocytoma grade IV, is the most common primary malignant brain tumor and one of the most lethal forms of cancer with a median survival rate of approximately 15 months after standard treatment. Currently, the chance of increasing the survival rate is found in therapy with doxorubicin (DOX) delivered to the central nervous system by polymeric carriers.